Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

37.41 -1.02 (-2.67%)
Streaming Delayed Price Updated: 10:45 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 Next >
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
7 Small-Cap Stocks that Wall Street Loves for Good Reason
As small-cap stocks start to catch up to the market rally, it's time to look at seven small-cap stocks that Wall Street loves. 
Via InvestorPlace
2 Biotech Stocks That Could Soar in December
These two biotechs have important catalysts coming up in December. 
Via The Motley Fool
What 6 Analyst Ratings Have To Say About Structure Therapeutics
Via Benzinga
4 Analysts Have This to Say About Structure Therapeutics
Via Benzinga
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
The Best-Performing U.S. IPOs Of 2023
In 2023, there were 154 IPOs on the U.S. stock market. Here is a look at some of the best initial public offerings from last year. 
Via Talk Markets
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
It has genuine struggles ahead, but it has some actual value in hand as well. 
Via The Motley Fool
7 Small-Cap Stocks That Wall Street Loves for Good Reason
The market rally is showing signs of broadening to include small-cap stocks, here are seven that analysts are upgrading 
Via InvestorPlace
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday. The Dow traded up 0.01% to 37,307.40 while the NASDAQ rose 0.71% to 14,919.07.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in metastatic... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.14% to 37,356.29 while the NASDAQ rose 0.25% to 14,851.19. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Novo Nordisk's Potential Obesity Drug Rival Structure Therapeutics Stock Tanking Today?
Structure Therapeutics Inc (NASDAQ: GPCR) shares are trading lower after the company provided a comprehensive development program update for its highly selective oral GLP-1  
Via Benzinga
Dow Gains Over 50 Points; Nippon Steel To Acquire U. S. Steel
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.15% to 37,362.28 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
The company is hoping to break into the pack with an oral GLP-1 agonist. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
Some of the most explosive opportunities can be found in biotech stocks. In fact, as we head into New Year 2024, here are three to consider. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
Should You Still Buy the Nasdaq's Best-Performing October Stocks?
Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them. 
Via The Motley Fool
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2023
Via Benzinga
BMO Capital Maintains Outperform Rating for Structure Therapeutics: Here's What You Need To Know
Via Benzinga
Why Shares of Structure Therapeutics Are Up Monday
The stock climbed for the second straight day after the company reported positive trial data for its weight-loss therapy drug. 
Via The Motley Fool
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.